

X X - 1 (10) 3 . 100
30 . 3 (1:10) « » 3 . 100
9]. [, : 1,5 , -
, - 1 , 1,5 , -
, 1,5 , 1,5
, - , 1,5 -
40% (/). , -
, , , -
[4]. - , ,
, 0,2% 3% , 2,5-4% , 3,59% -
, - , 7-8% -
. X - , , , -
, , , -
- , , -
- , (.1). -
- (17) , , -
, , , , -
, , , , -
2 9 (- 37,2%, - 2, %) X X , , , -
271, 200 X X ((.2). -
43 , 200 , 2007, () - 12-13, 30%, , -
2009). , , -
(IL-1p, IL-4) - (). -
» - (-), « IL-1p, -
INFa IL-4 PR , -
1200 Sanofi Diagnostics Pasteur (- , , -
) () , , , -
() (A) , , , -
() ^) - () , , , -
() ^ / , ^ (- , , , -
. , 1991). , , (-
X X: () (- , , , -
). « ...», , , (.3). ,



7.

23 (21,5%)
 , 15 (13,8%) -
 (70 -64,7%)
 853,9±10,6 (3062±32;
 <0,01), 3,58

IL-1P 2,3
 (22,2±1,6 /)
 (p>0,05).

1,6 (26,74±1,5 / ; <0,05)
 (p<0,05).

IL-1P

IL-4

IL-4

1,4 (<0,01)
 (45,1±1,5 /),
 IL-4 (p<0,05).

Microsoft

Office 97, Microsoft Exel Stadia .1/ propf Statistica.

98,7%

X X

(9 - 91,0%), (9 - 9, %), (94 - ,7%),
 (7 - 2,4 %), (- 1, %).

3 (3,4±0,25 /),
 1,6 (5,5±0,2 /).

X X

2,7 (9,7±0,2 /),
 1,8

IL-1b

2, (1,7±2,1 / ; <0,01),
 20,0±1,1 / ; <0,01),
 3,3 (44,1± , / ; <0,01).

1,3

IL-4 (0,9±2,1 /

44,7±1, / ; <0,01),

IL-1p/IL-4

2,9 (p<0,01),

/Hb, - 27,8±0,5 /Hb,
 307±11 /Hb, 1,2
 1,4

A

X X

(20,5±0,8 /Hb; <0,05).

2845±12,

- 1144±23,

A

3±0,3 / (,2±0,2 / ; <0,01),
 17,9±0, / (,2±0,1 / ; <0,001).

1.

A

4 ±9,0

(IL-1P,)

/ Hb (4 ±1 / Hb; <0,0)

1 , ±0,

(IL-4).

/ Hb (2 ,4±1,2 / Hb; <0,01).

2.

3.

1. ...
 2. ...
 3. ...
 4. ...
 9. ... 4. ... 5-10.
 4. ...
] / ... // -2009. : www.

4.

likar-info.ua /articles/2009/ 01firsov.htm.
 6. ... / ... , 2000.-448 .
 7. ...
 // -2008.- 1.- . 126-129.
 8. Fox K. Guidelines on the management of stable angina pectoris. The Task Force on the Management of Stable Angina Pectoris of European Society of Cardiology / K. Fox // Europ. Heart J. - 2006. -Vol. 27, 11. - . 1341-1381.
 9. Cholecystitis, biliary tract surgery an pancreatitis: overview // Obstet. Gynecol.- 2004.-Vol. 104.-P. 17-24.
 10. Schirmer B.D. Cholelithiasis and cholecystitis // B.D. Schirmer, K.L.Winters, R.F. Edlich // Y. Long Term Eff. Med.implants.- 200.- ? . 1 (3).-P.329-338.

06.12.2012

616.366-002-036.12:616.12-005.4

(IL-1 ,)

(IL-4),

« »

1 ,)

(-4),

« »

K.N. Kompaniets, L.N. Ivanova
PATHOGENETIC EXPLANATION OF THE USE OF MODERN
COMPLEX PLANT DRUG «HELISKAN» AT PATIENTS
WITH CHRONIC NON-CALCULOUS CHOLECYSTITIS IN
COMBINATION WITH ISCHEMIC HEART DISEASE

Key words: chronic non-calculous cholecystitis, ischemic heart disease, medical treatment, heliskan.

In the article the examination of patients with CAC in combination with IHD was given. The rise of level of proinflammatory (IL-1p, TNF-) cytokines in the blood serum on background of relative incompetence of antiinflammatory cytokine (IL-4), disbalance of the peroxidation of lipids and the antioxidant protection with the rise of the MDA and DC in the blood of examined people, the rise of the KT activity, the decline of SOD and integral coefficient F were recorded. The pathogenetically grounded use of modern plant drug Heliskan in the complex of medical treatment of patients with combined pathology was forwarded to the positive dynamics of the studied biochemical and immunological indexes.